Tokyo Tape
Sign in
← Medipal Holdings

Quarterly report · Q2

7459.TEDINET S100PLGZ
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥1.69T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥3.29T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.64T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥25.5bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥24.3bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥33.3bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥62.0bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥33.6bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥33.3bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥34.0bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥17.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥18.5bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥21.9bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥23.8bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.74Tat 2022-09-30Cons.Assets
Total assets¥1.71Tat 2022-03-31Cons.Assets
Total assets¥1.72Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.06Tat 2022-09-30Cons.Liabilities
Total liabilities¥1.06Tat 2022-03-31Cons.Liabilities
Net assets / equity¥674.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥649.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥657.2bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥221.2bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥243.2bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥238.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥260.4bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥239.6bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥240.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥9.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥61.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥24.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥5.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥24.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥18.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥16.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥82.512022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.132022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥140.142021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥88.232021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.252021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥77.562022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥131.412021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥82.792021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio31.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.0%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥191m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥554.9bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥554.7bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥174m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.10T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥25.4bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥1.9bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥304m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥35.9bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥35.9bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥531.6bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥531.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥175m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥13.3bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.08T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.08T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥9.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.65T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.64T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥24.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Extraordinary lossCurrentYTDDuration3566000000JPY
Income before income taxesPrior1YTDDuration33958000000JPY
Income before income taxesCurrentYTDDuration33342000000JPY
Income taxes currentPrior1YTDDuration14736000000JPY
Income taxes currentCurrentYTDDuration15829000000JPY
Income taxes deferredPrior1YTDDuration-4530000000JPY
Income taxes deferredCurrentYTDDuration-4391000000JPY
Income taxesPrior1YTDDuration10205000000JPY
Income taxesCurrentYTDDuration11438000000JPY
Profit lossPrior1YTDDuration23753000000JPY
Profit lossCurrentYTDDuration21904000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration5227000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration4579000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration18525000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration17324000000JPY
Profit lossPrior1YTDDuration23753000000JPY
Profit lossCurrentYTDDuration21904000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration186000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration8909000000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration-1000000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration5000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-134000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-249000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration492000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration1103000000JPY
Other comprehensive incomePrior1YTDDuration542000000JPY
Other comprehensive incomeCurrentYTDDuration9769000000JPY
Comprehensive incomePrior1YTDDuration24295000000JPY
Comprehensive incomeCurrentYTDDuration31673000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration19340000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration26487000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration4955000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration5186000000JPY
Income before income taxesPrior1YTDDuration33958000000JPY
Income before income taxesCurrentYTDDuration33342000000JPY
Depreciation and amortization ope cfPrior1YTDDuration6984000000JPY
Depreciation and amortization ope cfCurrentYTDDuration7065000000JPY
Impairment loss ope cfPrior1YTDDuration60000000JPY
Impairment loss ope cfCurrentYTDDuration39000000JPY
Amortization of goodwill ope cfPrior1YTDDuration127000000JPY
Amortization of goodwill ope cfCurrentYTDDuration127000000JPY
Increase decrease in provision for loss on guarantees ope cfPrior1YTDDuration20000000JPY
Increase decrease in provision for loss on guarantees ope cfCurrentYTDDuration－JPY
Increase decrease in provision for bonuses ope cfPrior1YTDDuration-533000000JPY
Increase decrease in provision for bonuses ope cfCurrentYTDDuration-57000000JPY
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration-60000000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration571000000JPY
Increase decrease in provision for loss on disaster ope cfPrior1YTDDuration-363000000JPY
Increase decrease in provision for loss on disaster ope cfCurrentYTDDuration-405000000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration9000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass